Biology subjects

Altaf, I.

Publications and source records attributed to Altaf, I..

3 recordsLinked to original sources

bioRxiv2020

An assessment of efficacy of Iodine complex (Renessans) against SARS-CoV-2 in non-human primates (Rhesus macaque)

Renessans is an iodine complex which has proven in vitro antiviral activity including Anti-SARS-CoV-2 activity. The present study was designed to determine its efficacy against SARS-CoV-2 in monkeys (Rhesus macaque). A total of 14 monkeys were divided into four groups: A) Prophylactic group (n=03), (B) Treatment group (n=03), (C) infection control group (n=04) and (D) negative control group (n=04) and were housed in BSL-3 Animal facility while group D was housed at another animal house. Group A was administered with Renessans @ 2.85 mg/7 kg from 5 days prior to the infection to 08 days post infections (DPI). Group B was administered with Renessans from 03-08 DPI @ 2.85 mg/7 kg. Group C was administered with WIF only. The infection @ 2 x 106 TCID of SARS-CoV-2 was given to all group monkeys through intranasal and oral route under anesthesia. Nasal swab samples (at different times) and fecal matter on daily basis were collected for the detection of SARS-CoV-2 through real-time quantitative PCR. Three monkeys (one from each of group A, B and C) were euthanized at 07 DPI to determine the gross pathological lesions and SARS-CoV-2 detection from internal tissues. Nasal swabs from all the monkeys from group A, B and C were positive for SARS-CoV-2 at 02 and 07 DPI (Day 05 of treatment). At 14 DPI, all (100%) nasal swabs from group A were negative for SARS-CoV-2 while 50% and 100% were positive from group B and C, respectively. At 21 DPI, monkeys from group B were negative and all in group C were still positive for SARS-CoV-2. Similarly, fecal matter of monkeys in group A and B was returned negative in significantly lesser time as compared to monkeys from infection control group. Based on these research findings it is concluded that the Renessans has in-vivo SARS-CoV-2 activity and may result in early clearance of SARS-CoV-2. Therefore, a clinical trial of the drug in COVID-19 patients may reveal its anti-COVID-19 potential.

microbiology↗

bioRxiv2020

An in vitro assessment of anti-SARS-CoV-2 activity of oral preparations of iodine complexes (RENESSANS)

Since the emergence of CoVID-19 pandemic in China in late 2019, scientists are striving hard to explore non-toxic, viable anti-SARS-CoV-2 compounds or medicines. We determined In Vitro anti-SARS-CoV-2 activity of oral formulations (syrup and capsule) of an Iodine-complex (Renessans). A monolayer of vero cells were exposed to SARS-CoV-2 in the presence and absence of different concentrations (equivalent to 50, 05 and 0.5 g/ml of I2) of Renessans. Anti-SARS-CoV-2 activity of each of the formulation was assessed in the form of cell survival, SARS-CoV-2-specific cytopathic effect (CPE) and genome quantization. With varying concentrations of syrup and capsule, a varying rate of inhibition of CPE, cells survival and virus replication was observed. Compared to 0.5 g/ml concentration of Renessans syrup, 5 and 50 g/ml showed comparable results where there was a 100% cell survival, no CPEs and a negligible viral replication ({Delta}CT= 0.11 and 0.13, respectively). This study indicates that Renessans, containing iodine, may have potential activity against SARS-CoV-2 which needs to be further investigated in human clinical trials.

microbiology↗

bioRxiv2020

Evaluation of cytotoxic, antiviral effect and mutagenic potential of a micronutrient combination in vitro cell culture

Background Micronutrients are essential for the body to produce enzymes, hormones and other substances essential for proper growth and development. Iodine, potassium iodide and ascorbic acid are ones of the most important in global public health terms. However, their lack represents a major threat to the human and animal health.Methodology Antiviral, cytotoxic and mutagenic activity of commercially available micronutrient combination consisting of iodine, ascorbic acid, potassium iodide and excipients was evaluated. Commercial preparation of micronutrient combination was compared with self-prepared micronutrient preparation. MTT assay was used to evaluate the cytotoxicity of all the preparation. Confluent monolayer of Chicken Embryo Fibroblasts grown in 96-well cell culture plates were treated with ten concentrations of each preparation in triplicate manner and was used to determine the viability of the cells and cell survival percentage. Antiviral efficacy was determined against influenza virus H9N1 strain by virus infection and subsequent cell viability assay. Furthermore, mutagenicity was measured by bacterial reverse mutation analysis by Ames test using two strains of Salmonella typhimurium TA100 and TA 98 with and without S9. After appropriate incubation, number of revertant colonies per plate were counted in triplicate manner and MF was calculated.Results Our combination showed cytotoxicity at doses higher than 11.71ug/ml while showed significant antiviral efficacy at concentrations of 11.71ug/ml, 5.86ug/ml, 2.93ug/ml and 1.4ug/ml which faded away at lower dilutions. Commercially available preparation was found to be non-mutagenic in our experiment.Conclusions Combination consisting of iodine, ascorbic acid, potassium iodide is effective in the treatment of viral infections.Competing Interest StatementThe authors have declared no competing interest.View Full Text

pharmacology and toxicology↗